US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line
Campaigners hit out at high price for controversial treatment that has divided scientists
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA
Keeping people independent and connected for longer can improve wellbeing and ultimately reduce demand
Oxford research finds Covid-19 44% more likely to cause psychiatric and neurological problems than flu
Difficult questions concerning dementia patients, their families and carers animate and bedevil Kristof Bilsen’s film
Fast-track testing in care homes is vital to stop the damage visitor restrictions are doing
Scientists discover way of creating the brain nerve cells that control movement and thought
Setback deals another blow to most common hypothesis about causes of the disease
Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab
Biogen says seeking approval for aducanumab hails ‘turning point’ in fight against disease
I have taken over the management of my mother’s finances under a power of attorney which she granted
How can business do more to accommodate workers with a dementia diagnosis? Also: researchers seek ways to tackle problems of underdiagnosis; tech leads the charge to protect people’s independence
There is a host of new products available, from door sensors to clocks
A hospital worker recalls being forced out after dementia diagnosis
Clive Cookson looks at future prospects for identifying more sufferers earlier
Imaginative fixes like virtual train rides plug only some of the funding gaps
Failing to make reasonable adjustments to help staff is against the law and bad for business
Researchers are exploring new ideas on what causes the disease
People with dementia are rarely afforded the same status as other at-risk groups
There is no rule book to support employees with Alzheimer’s
Imperial College research finds some patients would benefit from Ritalin treatment
Governments must steer private funding towards difficult diseases
International Edition